AZD 2281,
AZD-2281,
AZD221,
AZD2281,
Lynparza,
olaparib,
Olaparib,
763113-22-0,
AZD2281,
Lynparza,
AZD-2281,
KU-0059436,
AZD 2281,
1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine,
Olaparib (AZD2281, Ku-0059436),
UNII-WOH1JD9AR8,
4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one,
AZD2281(olaparib),
WOH1JD9AR8,
KU-59436,
CHEBI:83766,
MFCD13185161,
4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One,
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one,
937799-91-2,
J-503540,
4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one,
4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one,
OLAPARIB cpd,
Olaparib [USAN:INN],
Acylpiperazine analogue, 47,
Olaparibum,
4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one,
Lynparza (TN),
09L,
4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one,
4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluoro-phenyl]methyl]-2H-phthalazin-1-one,
PubChem19148,
Olaparib (AZD2281),
Olaparib - AZD2281,
cc-16,
AZD-2281 (Olaparib),
Olaparib (JAN/USAN/INN),
MLS006010185,
SCHEMBL426568,
CHEMBL521686,
GTPL7519,
BDBM27566,
CTK8B3857,
KS-00000HXY,
AOB1085,
EX-A002,
FDLYAMZZIXQODN-UHFFFAOYSA-N,
BCPP000360,
HMS3654G13,
BCP01872,
ABP000423,
AN-493,
ANW-43329,
AZ2281,
GP0126,
NSC747856,
s1060,
ZINC40430143,
AKOS005145764,
AC-7939,
ACN-032229,
AN-5279,
API0024518,
BCP9000363,
CS-0075,
DB09074,
EX-7210,
KU59436,
NSC-747856,
QC-2660,
RL04905,
SB14617,
SS-4573,
AZD2281,Olaparib, KU-0059436,
NCGC00238451-01,
NCGC00238451-02,
NCGC00238451-09,
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one,
4CA-0938,
AK-40514,
BC245405,
BR-40514,
EN002690,
HY-10162,
Olaparib (AZD2281, KU0059436),
SC-65060,
SMR004701291,
SY040527,
AB0009952,
AB1009702,
AJ-101717,
AX8162101,
KU0059436,
A9666,
BB 0260909,
FT-0083489,
FT-0651458,
SW218142-2,
EC-000.2324,
MFCD13185161 (95%),
D09730,
S-3781,
S-7836,
Z-3275,
AZD2281(olaparib)/AZD-2281/KU0059436,
I06-2362,
BRD-K02113016-001-08-9,
BRD-K02113016-001-09-7,
1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1,
AZD 2281|||KU 0059436|||KU 59436,
(2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-,
1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-,
4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one,
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one,
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-2H-phthalazin-1-one,
Olaparib [INN],
D0J9HW,
AZD221,
C24H23FN4O3,
KU 59436,
Olaparib, 99%, PARP inhibitor - 1G 1g,
A4154,
KU 0059436,
A10111,
|A-Chloro-p-tolunitrile; 4-Cyanobenzyl chloride,
C531550,
Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281,
4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one,
4-[[3-[[4-(Cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone,